Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1826186 | 0.91 | KMT2A (0.37) | CASP3KMT2ASMN1; SMN2SLC15A1EPHX2 | |
| SCHEMBL1821936 | 0.91 | CASP3 (0.39) | CASP3KMT2ASLC15A1PTPN1CDC25B | |
| SCHEMBL1825077 | 0.91 | CASP3 (0.37) | CASP3KMT2AEPHX2CA1CA2 | |
| SCHEMBL1828730 | 0.90 | CASP3 (0.40) | CASP3KMT2AEPHX2CA1CA2 | |
| SCHEMBL1824997 | 0.89 | LMNA (0.38) | CASP3KMT2ASMN1; SMN2SLC15A1 | |
| SCHEMBL1822877 | 0.88 | KMT2A (0.45) | KMT2ASMN1; SMN2SLC15A1FAAHCA1 | |
| SCHEMBL1826270 | 0.88 | CASP3 (0.37) | CASP3KMT2ASMN1; SMN2EPHX2CA1 | |
| SCHEMBL3576937 | 0.88 | KMT2A (0.38) | CASP3KMT2ASMN1; SMN2EPHX2PTPN1 | |
| SCHEMBL1823965 | 0.87 | CASP3 (0.36) | CASP3KMT2AEPHX2CA1CA2 | |
| SCHEMBL3578426 | 0.84 | KMT2A (0.43) | KMT2ASMN1; SMN2SLC15A1FAAHCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714157-B2 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20070270603-A1 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-11-22 | — | — | US | disclosed |
| US-7271280-B2 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-18 | — | — | US | disclosed |
| EP-1481967-A1 | PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS | Sumitomo Chemical Company, Limited (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040158093-A1 | Process for preparing a biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158093-A1 | Process for preparing a biaryl compound | CYP1B1, REL, CYP2F1 | CASP3 1512/4885KMT2A 1068/4885SMN1; SMN2 2274/4885 |
| US-20070270603-A1 | Process for preparing a biaryl compound | CYP4A11, CYP4B1, CYP51A1 | CASP3 854/4885KMT2A 1084/4885SMN1; SMN2 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.